National Cancer Drugs Fund Application Form –
Enzalutamide
for Castrate-resistant Metastatic Prostate Cancer
(chemotherapy naïve for metastatic disease)
Author(s)
David Thomson
Owner
Chemotherapy Clinical Reference Group
Version Control
Version Control
Date
Revision summary
Ver0.1
14 Jul 2014
Draft for discussion
Ver1.0
21 Jul 2014
Final version
Ver1.1
24 Oct 2014
ICD-10 code corrected; criteria 2 updated
Change to current version
Criteria
Changes
2
Criteria split into a. and b. to allow for non-histological confirmation
National Cancer Drugs Fund – Application Form 24 Oct 2014
Enzalutamide for Castrate-resistant Metastatic Prostate Cancer
Chemotherapy naïve for metastatic disease
Page 1
National Cancer Drugs Fund Application Form –
Enzalutamide
for Castrate-resistant Metastatic Prostate Cancer
(chemotherapy naïve for metastatic disease)
Instructions to Consultants: Please fill in each section of the form electronically and save the
document with your own file name. [If you continue typing the boxes will enlarge to contain the text].
Please send electronically to ______________________. Please also send copies to your Trust’s link
accountant / corporate contracting team.
Security of Patient Identifiable Information: The patient will be identified by their NHS number only.
Please do not include any other patient identifiers for confidentiality reasons. All communication must be
sent to the Cancer Drugs Fund Office via secure e mail accounts: that is from an nhs.net account to the
____________ account.
Receipt of Application: The sender of the application will receive an acknowledgement, together with
details of the unique Cancer Drugs Fund reference.
Cancer Drugs Fund Policy: To check the status of a particular therapy please check the Cancer Drugs
Fund Policy at _________________
Applications will be subject to Clinical Audit arrangements.
BY TICKING THESE BOXES AND SUBMITTING THE APPLICATION THE CLINICIAN IS
CONFIRMING THE PATIENT MEETS ALL THE CRITERIA BELOW. IT SHOULD BE NOTED THAT
THE SACT DATASET WILL BE USED TO MONITOR THAT THESE CRITERIA ARE BEING MET.
Approved Treatment Required for chemotherapy naïve Castrate-resistant Metastatic
Prostate Cancer
TICK
All 8 conditions must be met
1. Application made by and first cycle of systemic anti-cancer therapy to be
prescribed by a consultant specialist specifically trained and accredited in the
use of systemic anti-cancer therapy
2. a. Histologically/ cytologically confirmed adenocarcimoma of the prostate OR
b. Clinical suspicion of prostate cancer is high due to high PSA value
(>100ng/ml) and evidence of bone metastases (identified by a positive isotope
bone scan or sclerotic metastases on plain radiographs)
3. Documented metastatic disease
4. Progressive disease despite the continued use of LHRH analogues or a
previous bilateral orchidectomy
5. No previous chemotherapy for metastatic disease
6. Performance status 0 or 1
7. Asymptomatic (0 or 1) or mildly symptomatic (2-3) as scored on the Brief Pain
Inventory Short Form question 3
8. No previous treatment with abiraterone unless abiraterone has had to be
stopped within 3 months of its start solely as a consequence of dose-limiting
toxicity and in the clear absence of disease progression
Consultant Approval (email authority)
Patient Consent Obtained (date of letter – copy to be retained on patient file)
National Cancer Drugs Fund – Application Form 24 Oct 2014
Enzalutamide for Castrate-resistant Metastatic Prostate Cancer
Chemotherapy naïve for metastatic disease
Page 2
Proposed Start Date for Therapy (add clinic date)*:
Consultant details*
(including signature or
email confirmation)
Name:
Hospital:
Address:
Post Code:
Telephone:
Nhs.net
Trust Pharmacist details of the Trust where
the patient will be
treated*
Mandatory - NHS No*:
Mandatory – Patients
date of birth*
Optional – Hospital No.
Clinical Commissioning
Group*
Patient’s GP*
(name, address,
telephone)
Name:
Hospital:
Address:
Post Code:
Telephone:
Nhs.net
NHS No:
DOB:
Hospital No:
CCG Name:
Name:
Address:
Post Code:
ICD-10 Code*
C61 – Malignant neoplasm of prostate
HRG Code
Completion of items marked with * is mandatory. Failure to complete these items may
mean that payment is not made.
National Cancer Drugs Fund – Application Form 24 Oct 2014
Enzalutamide for Castrate-resistant Metastatic Prostate Cancer
Chemotherapy naïve for metastatic disease
Page 3